Clinical Trial Update: A Phase 1 Study to Explore the Cardiac Pharmacodynamics of MT-1303 [Phase 1]

View source ↗

Summary

This document reports a completed Phase 1 study evaluating the cardiac pharmacodynamics of MT-1303 in relapsing-remitting multiple sclerosis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• MT-1303

Snippet

Sponsor: Tanabe Pharma Corporation | Conditions: Relapsing-remitting Multiple Sclerosis | Phase 1 | Status: COMPLETED